T1	Participants 57 98	patients with active rheumatoid arthritis
T2	Participants 353 509	Patients ages ≥18 years with active RA with an inadequate response to ≥1 tumor necrosis factor inhibitor (TNFi) and receiving stable background methotrexate
T3	Participants 1854 1921	patients with active RA and a previous inadequate response to TNFi.
